健脾祛湿方联合美沙拉嗪治疗克罗恩病疗效观察  

Clinical Observation on Spleen-invigorating Dampness-eliminating Prescription and Mesalazine in Treating Crohn’s Disease

作　　者：盛好[1] 拉扎提•巴合提 徐杰 雷云霞[1] SHENG Hao;Lazhati•BAHETI;XU Jie;LEI Yunxia(TCM Hospital Affiliated to Xinjiang Medical University,Urumqi 830000,China)

机构地区：[1]新疆医科大学附属中医医院,新疆乌鲁木齐830000

出　　处：《西部中医药》2022年第1期115-118,共4页Western Journal of Traditional Chinese Medicine

基　　金：2018年新疆维吾尔自治区卫计委青年医学科技人才专项科研项目(2018Y47)。

摘　　要：目的:观察健脾祛湿方联合美沙拉嗪治疗克罗恩病(Crohn’s disease,CD)的效果。方法:将82例克罗恩病患者随机分为试验组和对照组各41例,对照组予美沙拉嗪干预,试验组在对照组干预基础上配合健脾祛湿方治疗,12周后比较两组患者CD活动指数(CDAI)评分和CD简化内镜(SES-CD)评分、分泌型磷脂酶A2(secretory phospholipase-A2,sPLA2)、红细胞沉降率(erythrocyte sedimentation rate,ESR)、C反应蛋白(C-reaction protein,CRP)、白细胞介素6(interleukin-6,IL-6)、肿瘤坏死因子α(tumor necrosis factor-α,TNF-α)和单核细胞趋化因子1(monocyte chemoattractant protein-1,MCP-1)的含量。结果:治疗后试验组CDAI和SES-CD评分较对照组低,差异具有统计学意义(P<0.01);试验组sPLA2、ESR、CRP低于对照组,差异具有统计学意义(P<0.05);与治疗前比较,两组患者IL-6、TNF-α和MCP-1水平均下降,差异具有统计学意义(P<0.01);两组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论:健脾祛湿方联合美沙拉嗪能更好地改善CD患者症状,改善炎症状态,且安全性良好。Objective:To survey clinical effects of spleen-invigorating dampness-eliminating prescription and mesalazine in the treatment of CD.Methods:All 82 CD patients were randomized into the experiment group and the control group,41 cases each group,the control group accepted the intervention of mesalazine,and the experiment group took spleen-invigorating dampness-eliminating prescription based on the intervention of the experiment group,to compare CDAI scores,SES-CD scores,sPLA2,ESR,CRP,IL-6,TNF-αand MCP-1 between both groups over 12 weeks.Results:CDAI and SES-CD scores of the experiment group were lower than these of the control group after treating,and the difference had statistical meaning(P<0.01);the experiment group was lower than the control group in sPLA2,ESR and CRP,and the difference was statistically significant(P<0.05);Compared with before treating,the levels of IL-6,TNF-αand MCP-1 lowered in the two groups,and the difference had statistical meaning(P<0.01);the difference had no statistical meaning in the incidence of adverse reaction between both groups(P>0.05).Conclusion:Spleen-invigorating dampness-eliminating prescription and mesalazine could improve the symptoms of the patients and inflammatory state with good safety.

关 键 词：克罗恩病 健脾祛湿方 美沙拉嗪 临床疗效 

分 类 号：R574[医药卫生—消化系统]